Racquel Bracken

Racquel Bracken joined Venrock in 2016 and focuses on pharmaceutical and biotech investments, as well as company creation. She currently serves on the Board of Cyteir Therapeutics, Prothelia and Federation Bio, a company she co-founded and initially served as CEO. She is also a Board Observer at Inscripta. Prior to Venrock, Racquel was an early employee of Clovis Oncology, a biopharmaceutical company focused on acquiring, developing and commercializing targeted small molecule therapies in combination with companion diagnostics. She held a variety of business development and commercial roles and was responsible for the acquisition of four pipeline products, and led the commercial launch efforts for the PARP inhibitor program in ovarian cancer.

Earlier in her career, Racquel was on the investment team at Domain Associates where she focused on early-stage healthcare investing. During her tenure there, Racquel also led business development at Calixa Therapeutics (acquired by Cubist Pharmaceutical). Prior to joining Domain Associates, she was a consultant with Easton Associates (now Navigant Consulting), a management consultancy dedicated to the medical industry.

Racquel is an avid backcountry skier, mountaineer, and mountain biker as well as a supporter of high school debate programs. She holds a bachelor’s degree in molecular and cellular biology from Harvard University and is also a member of the Kauffman Fellows.